Zeynep Oruc (Zeynep Oruç)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Locally Advanced

Radical Prostatectomy

Ejection Fraction

Placebo Controlled

Top Venues

Postgraduate medicine

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Zuhat Urakci, Senar Ebinç, Zeynep Oruc, Ziya Kalkan, Muhammet Ali Kaplan, Mehmet Küçüköner, Abdurrahman Işıkdoğan
Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors. Postgraduate medicine 136 (2) (2024)
Zuhat Urakci, Senar Ebinç, Zeynep Oruc, Ziya Kalkan, Muhammet Ali Kaplan, Mehmet Küçüköner, Abdurrahman Işıkdoğan
Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors. Postgraduate medicine (2024)
Zuhat Urakci, Senar Ebinç, Zeynep Oruc, Ziya Kalkan, Muhammet Ali Kaplan, Mehmet Küçüköner, Abdurrahman Işıkdoğan
Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors. Postgraduate medicine 136 (2) (2024)
Zuhat Urakci, Senar Ebinç, Zeynep Oruc, Ziya Kalkan, Muhammet Ali Kaplan, Mehmet Küçüköner, Abdurrahman Işıkdoğan
Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors. Postgraduate medicine (2024)
Senar Ebinç, Zeynep Oruc, Yasin Sezgin, Oğur Karhan, Erkan Bilen, Halis Yerlikaya, Ziya Kalkan, Zuhat Urakci, Mehmet Küçüköner, Muhammet Ali Kaplan, Abdurrahman Işıkdoğan
Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy. Future oncology (London, England) 18 (30) (2022)
Zeynep Oruc, M Ali Kaplan, Mustafa Karaağaç, Neslihan Özyurt, Ali Murat Tatlı, Ali Osman Kaya, Serkan Menekşe, Engin Kut, Sinan Koca, Özlem Nuray Sever, İrem Yasin, Senar Ebinç, Esra Zeynelgil, Abdullah Sakin, Nazım Serdar Turhal, Abdurrahman Isikdogan
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future oncology (London, England) 17 (13) (2021)